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Introduction
Extra-corporeal organ perfusion is an area gaining traction 
in transplantation, with increasing evidence showing 
superiority over cold storage of donor organs, and the 
potential for organ recovery and repair. This technology is 
currently utilised in the procurement of heart, lungs, liver 
and kidneys with varying outcomes. This review will focus 
on the current progress in device technology for heart 
transplantation.
A history of heart transplant
The first heart transplant was performed in 1967 by Dr. 
Christiaan Barnard, in Groote Schuur Hospital, Cape 
Town (1,2). The donor was a young lady who sustained 
irrecoverable traumatic brain injury; and the recipient, a 
55-year-old man with ischaemic cardiomyopathy. In the 
absence of brain-death legislation at the time, withdrawal 
of life support and subsequent rapid procurement of the 
donor heart upon asystolic arrest occurred in an adjacent 
operating room to that of the recipient’s transplant 
procedure. Whilst the recipient only survived 18 days, 
this was the ‘proof-of-concept’ that resulted in widespread 
adoption of heart transplantation globally. However, early 
results were universally poor, resulting in the abandonment 
heart transplantation by many units. It was not until the 
1980’s when there was a revival of heart transplantation 
with the introduction of brain death legislation (3), clinical 
acceptance of criteria to establish brain-stem death and 
more importantly, the discovery of cyclosporin for the 
immunosuppressive therapy for acute graft rejection. 
Today, heart transplantation remains the gold standard 
treatment for end stage heart failure refractory to medical 
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therapy with reported 1-year survival of 85–93%, long-
term survival up to 69% at 10 years (4,5). Despite the 
increase prevalence of heart failure, transplant numbers 
have not seen a comparable rise. This is due to a shortage 
of donor hearts which can be attributed to improved road 
safety, continued low organ donation rates and increasingly 
older donors with multiple co-morbidities. Whilst, raising 
awareness for organ donation has shown an improvement 
in overall donation numbers, there remains a high demand 
with growing transplant wait-lists leading to the necessary 
expansion of current acceptable donor criteria (marginal 
criteria) and inclusion of a new category of organ donors, 
donation after circulatory death (DCD) (5-8). Whilst the 
small initial historical cohort of heart transplants were from 
this DCD pathway, the donors and matched recipients were 
in these instances co-located in adjacent operating theatres. 
This practice was subsequently abandoned due to the 
logistics of donor transfer to the recipient hospital and with 
the adoption of long-distance organ procurement with cold 
static preservation of organs during transportation.
One of the biggest concerns associated with the use of 
these marginal or extended-criteria organs is the unknown 
risk of graft failure and graft dysfunction post implantation. 
This is particularly pertinent in the DCD cohort, as these 
donor hearts have been exposed to an inevitable period of 
warm ischaemia prior to the institution of cardio-protective 
solution. The advent of ex-situ machine perfusion (MP) 
allows these organs to be reanimated and assessed prior 
to consideration for transplantation. The use of MP has 
led to the first successful distant procurement DCD heart 
transplantation in 2014 by Dhital and co-workers from St 
Vincent’s Hospital, Sydney, Australia (9). To date, 100 cases 
of DCD heart transplants has been performed across 6 units 
in Australia, the UK and Belgium.
MP and heart transplantation
The concept of ex-situ perfusion has long been desired 
and is potentially the ideal preservation strategy for donor 
organ management. Stemming from Langendorff’s isolated 
heart perfusion model in mammals (10), which has been 
paramount in the study of ischaemic reperfusion injury (IRI) 
and heart transplantation, the recent development of clinical 
MP devices has been long in the making. The advantages 
of MP are derived largely from its ability to provide 
continuous circulation to the organ thereby protecting it 
from ongoing ischaemic injury. Furthermore, it provides a 
platform for strategies to mitigate reperfusion injury, detect 
anatomical abnormalities, uncover physiological dysfunction 
and ‘recover’ borderline organs through pharmacotherapy.
Currently, cold static storage (CSS) of donor heart 
remains the standard practice in most transplant 
units (11). The donor heart is flushed with preservation 
solution in-vivo, rapidly explanted and stored in cold 
saline or preservation flush solution at 4 ℃. The organ 
is expediently transferred to the recipient hospital for 
implantation. Hearts procured in this method have a 
tolerable ischaemic period between 4–6 h, after which the 
organ deterioration leads to higher risk of graft failure and 
poorer outcomes in the recipient. Furthermore, using the 
current method of cardiac preservation, the donor heart is 
assessed in-vivo with no further evaluation once the heart 
has arrested and is stored, discounting any occult disease or 
injury that may have occurred during the retrieval process 
or in transit. Despite this, CSS hearts have shown consistent 
outcomes and is a reliable and cost-effective method of 
organ procurement particularly when there is no suspicion 
of organ marginality.
In contrast, the use of MP in the procurement of donor 
heart is currently limited to a few centres in the United 
States and Europe. At present, there is only one device 
available for clinical use, which is the Transmedic Organ 
Care System (OCS) Heart. This system uses a combination 
of donor blood and a proprietary solution as perfusate 
for the heart at mild hypothermia (34 ℃). The benefit of 
normothermic perfusion is its ability to reanimate the heart 
and allow the clinician to perform functional assessment 
of the donor heart. At present, a combination of visual 
inspection, metabolic and flow parameters are used to 
determine organ viability. As oppose to the stringent time 
limitation in CSS, normothermic machine perfusion (NMP) 
has enabled clinicians to logistically delay implantation time 
with no significant consequences (12). 
Role of MP 
Key benefit of MP is the ability to maintain perfusion 
of the heart, meeting the metabolic needs of tissues and 
limiting progression towards irreversible cellular injury and 
death. In the marginal donation after brain death (DBD) 
setting, donor haemodynamics are managed carefully until 
the time of procurement, thereby limiting the duration of 
tissue ischaemia. Preservation flush is rapidly administered 
upon cross-clamping of the aorta to arrest cardiac activity, 
reducing the risk of ischaemic injury. The heart is rapidly 
explanted and installed on the device and flow is restored.
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The reanimated heart now receives antegrade coronary 
perfusion via retrograde filling from the aorta. Coronary 
effluent drains from the coronary sinus into the right 
atrium and follows the normal path of circulation into the 
right ventricle before being ejected into the cannulated 
pulmonary artery and then into the circuit reservoir. The 
device permits measurements of the following physiological 
parameters: ECG, haematocrit, SaO2, aortic flow, aortic 
pressure, coronary flow and temperature. Serial sampling 
from the arterial and venous ports of the circuit permits 
routine blood gas measurements including lactate levels. 
The target physiological and biochemical parameters are 
presented in Table 1.
Once flow and pressure on NMP have stabilised, the 
heart is periodically assessed with arterial and venous 
blood lactate measurements. Current recommendation by 
Transmedics OCS Heart are presented in Table 1. The heart 
is considered feasible for transplantation upon reaching 
the target lactate parameters and if there are no gross 
abnormalities on visual inspection.  The system allows for 
epicardial echocardiography and is also compatible for 
coronary angiography if required (14).
Standard brain-dead donors (DBD)
As discussed earlier, only one system utilising normothermic 
perfusion is currently available for clinical use. To date, 
more than 200 DBD and 100 DCD heart transplants have 
been performed using the OCS system (see Table 2). The use 
of OCS in the DBD setting has been extensively discussed 
previously by Messer et al. (15). To date, the PROCEED 
II and PROTECT II trial has shown non-inferiority when 
comparing NMP to CSS using the Transmedic OCS 
Heart. 
Marginal brain-dead donors (MBD)
MBD or extended criteria brain dead donor hearts have 
been utilised since 2000, with comparable survival to DBD 
as reported by multiple single centre studies (5,16-18). 
It is important to note however, that in these studies, the 
hearts were cold stored after procurement without the use 
of NMP. Furthermore, the inclusion and exclusion criteria 
were different in each study accounting for the variability 
in outcomes and is a key limitation to its wider application. 
Despite these shortcomings these studies suggest that hearts 
from older donors with mild ventricular impairment are 
feasible for transplantation.
When comparing the role of NMP in the recovery of 
MBD hearts, there are currently no comparison studies 
published. Single centre studies to date have shown 
comparable survival to DBD (19-21) where the key 
advantage of NMP is to eliminate the risk of prolonged 
ischaemic time thereby allowing access to farther donors 
which would have otherwise been refused. 
The EXPAND study is the only multicentre study 
comparing CSS and NMP in MBD donors. This is 
currently an ongoing study with a projected completion 
date in mid-2019. 
DCD donors
DCD donors are a new category of heart donors. In 
contrast to DBD donors, DCD donor hearts are exposed 
to prolonged periods of warm ischaemia, and as a result 
require functional assessment prior to transplantation. 
As the donor undergoes the process of circulatory arrest, 
these hearts exhibit severe right atrial and ventricular 
distension (22); furthermore, the period of warm ischaemia 
may result in irreversible myocardial injury. Iyer et al. have 
shown that porcine hearts exposed to more than 20 minutes 
of circulatory arrest is associated with irreversible cardiac 
injury, and through pharmacological conditioning this time-
frame can be prolonged to 30 minutes (23). 
In this category of donors, post asystolic functional 
assessment of the hearts is necessary. Currently, two 
methods of post-asystolic assessment and procurement 
are practiced. Figure 1 outlines the major process in both 
methods of organ retrieval and recovery.
Sydney direct procurement protocol (DPP) (7,24)
Once death is confirmed, the donor is rapidly transferred 
Table 1 Normothermic machine perfusion (NMP) target 
parameters for the initial management of organs (13)
Parameter Starting dose/target
Pump flow (L/min) 0.9–1.2 
Coronary flow (mL/min) 650–850 
Mean aortic pressure (mmHg) 60–90 
Overall lactate <5 mM with arterial > venous 
lactate
Manual/visual inspection Exclude palpable disease and 
obvious wall motion abnormality 
or arrhythmia
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to the operating room for organ procurement. 1.2–1.5 L of 
donor blood is collected centrally, followed by delivery of 
cardio-protective solution via the aortic root. The donor 
heart is topically cooled and explanted upon completion 
of the preservation flush. The heart is instrumented for 
NMP. Upon reperfusion, any arrhythmia and electrolyte 
imbalances are corrected. Coronary flow and aortic pressure 
targets are met by titrating aortic flow, adrenaline and 
adenosine infusions.
Papworth normothermic regional perfusion (NRP) (24,25)
The donor  i s  exped ient ly  br idged  onto  cent ra l 
extracorporeal membrane oxygenation (ECMO) after 
death ensues, with cross-clamping of the arch vessels to 
prevent cerebral perfusion. ECMO flow is maintained at 
5 L/min, with a target MAP >50 mmHg. The organs are 
resuscitated for a short period, after which a combination 
of biomarkers and functional assessment is performed. 
Hearts that demonstrate adequate recovery are flushed with 
cardioplegia solution of choice and following explanation is 
installed onto NMP for transportation.
Management of DCD hearts on NMP is largely similar 
to DBD hearts procured using NMP. Of note however is 
the importance of correcting any electrolyte imbalances 
in the perfusate, especially in the DCD group, which 
usually demonstrate significant acidosis, hyperkalaemia and 
hypercalcemia. Furthermore, in contrast to Transmedic’s 
recommendation to commence high dose of adenosine 
infusion in the DBD setting, within the DCD cohort, we 
have noted increase adrenaline requirement to counter a 
vasodilated coronary circulation with high coronary flow 
and a low perfusion pressure immediately post-reperfusion. 
To date, 100 cases of DCD heart transplantation has 
been performed over 6 centres between Australia, United 
Kingdom and Belgium. Current published outcome by the 
Papworth experience reported a comparable short term 
survival between the DCD and DBD cohorts with a 1-year 
survival of 86% in the DCD-DPP group, and 100% in 
the DCD-NRP arm vs. 96% in DBD group; ECMO use 
was reported at 12% (8). In Australia, we have performed 
27 cases of DCD heart transplantation using DPP with 
only one mortality (96% survival); ECMO support post-
transplant was 30% (n=8). Despite the excellent outcomes 
to date, uptake of DCD transplantation remains low due 
to the lack of more rigorous physiological and biochemical 
Table 2 Studies utilising NMP 
Study name (Centre) Year N (OCS) Donor criteria
PROTECT I (EU) 2006–2007 22 Standard
PROTECT II (EU) 2007–2008 20+ Standard
PROCEED I (US) 2007–2008 15 Standard
PROCEED II (US) 2011–2013 62 Standard
Berlin 2009–2013 20 Extended
Other German 2012– 13+ Extended
Harefield (UK) 2013– 17+ Extended
St Vincents (Aus) 2012– 10 Extended
EXPAND (US) 2015– 30+ Extended
St Vincents (Aus) 2014– 28 DCD
Papworth (UK) 2015– 32 DCD
Harefield (UK) 2015– 8 DCD
Wythenshaw (UK) 2017– 4 DCD (unpublished)
Manchester (UK) 2017– 3 DCD (unpublished)
Belgium (EU) 2018– 1 DCD (unpublished)
NMP, normothermic machine perfusion; OCS, Organ Care System; DCD, donation after circulatory death.
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Figure 1 Donation after circulatory death (DCD) organ retrieval pathways. The two existing DCD organ retrieval pathway—normothermic 
regional perfusion (NRP) and direct procurement protocol (DPP). The use of NRP is dependent on local jurisdiction. While DPP relies on 
normothermic machine  perfusion (NMP) for functional assessment, both pathways utilise NMP for transportation to the recipient hospital. 
1, WIT from systolic <90 mmHg (Australia); 2, administration of antemortem heparin is dependent on local legislation; and is not legal in all 
states in Australia; 3, stand-off period is variable between 2 and 5 min in Australia depending on donor location.
DCD Heart Donor Referral Criteria:
• Age ≤50 years
• Normal cardiac investigations (if available)
• Anticipated WIT <30 mins1
Withdrawal from Life Support
• Perimortem heparin2
• Stand-off period3
• Declaration of death
• Transport and identification
• Midline sternotomy
NRP:
• X-clamp head and neck arteries
• Establish Central ECMO
o Flow 5 L/min
o MAP >50 mmHg
o Temp ≥35 ℃
• Inotropy:
o Dopamine at 5 µg/kg/min












o PF 1–1.2 L/min
o CF 650–850 mL/min
o MAP 60–80 mmHg
• Inotropy:
o Adenosine or adrenaline (as 
required)
• Biomarkers:
o Serial lactate measurement
• Visual assessment:
o LV and RV contractility
On Back-table:
• Preparation for NMP
o Volume Loading on
o NMP + Correction of Metabolic 
Disturbances
o Aortic and pulmonary artery cannulation
• Closure of SVC and IVC
• Closure of RAA
• Insertion of LV vent
• Installation for NMP
Abbreviations:
ECMO: extracorporeal membrane oxygenation
WIT: warm ischaemic time
X-Clamp: cross clamp
MAP: mean arterial pressure
PAP: pulmonary artery pressure
CO: cardiac output  
TOE: transoesophageal echocardiogram
R/LV: right/left ventricle
RAA: right atrial appendage




• Blood collection 1.5–2 L
o RAA with two-stage cannula
• X-clamp ascending aorta
o Preservation flush via aortic root
o Topical hypothermia
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metrics, lack of surgical experience with MP and inability to 
fully assess ventricular function in working modality in the 
current state of the device.
Pre-clinical devices
Apart from the Transmedic OCS Heart™ which is currently 
used clinically, four other cardiac perfusion devices have 
been trialled in animal studies with good outcomes. All four 
devices utilise hypothermic machine perfusion (HMP) at 
4 ℃. These devices are listed in Table 3. 
HMP vs. NMP
While there are no studies comparing HMP to NMP in 
cardiac allograft preservation, both preservation techniques 
have demonstrated improved or comparable outcomes to 
CSS hearts. Current evidence suggests that the provision 
of oxygen renders better protection to cardiomyocytes, 
preserves cellular ATP stores and better maintains 
membrane conditions (34). Furthermore, the continuous 
perfusion prevents build-up of toxic metabolites (i.e., 
lactate and adenosine) which may contribute to poor 
ventricular function or serve as a substrate for the 
generation of free radicals upon reperfusion of the 
organ (29). Hearts preserved using HMP is maintained in 
the arrested state.
As oppose to NMP, due to the lower temperatures, 
sufficient oxygen delivery can be achieved using oxygenated 
crystalloid solution. The resulting cardiac oedema does 
appear to be readily reversible post-transplantation 
and has not been shown to affect detrimentally cardiac 
function (35). Furthermore, both systems currently lack a 
formal and objective method for functional assessment of 
the allograft. As currently used biomarker (i.e., lactate) does 
not necessarily reflect the functional ability of the organ (24), 
a more reliable marker or mode of assessment is needed.
Future of organ perfusion and future directions
The changing landscape of heart transplantation with 
greater utility of high-risk donor organs to address the issue 
of organ shortage has led to more stringent assessment of 
donor hearts.  The use of machine technology has allowed 
a 15–20% increase in transplant volumes by utilising 
hearts that were otherwise rejected. While the current 
NMP system is not without a significant price tag, overall 
cost saving through reduced hospital readmissions for 
management of decompensated heart failure may justify 
and promote greater use of organ perfusion systems (36). 
Further cost-benefit evaluation is required and may need 
case by case assessment. 
In regard to HMP versus NMP, whether maintaining 
the heart in the arrested state will provide better protection 
is a moot point, which leads to the most important issue 
being the inability for either systems to perform functional 
assessment in their current design configuration. This 
is especially pertinent when considering MBD or DCD 
Table 3 HMP devices in the pre-clinical phase
Device name Animal studies Human studies
Steen Heart Preservation System (Lund, 
Sweden)
Porcine DBD with 24 hours Non Ischaemic 
Hypothermic Perfusion (NIHP) followed by 
transplantation (26)
Heart transplantation using donor hearts 
preserved using NIHP (27); one successful 
clinical transplantation performed to date (28)
LifeCradle Heart Perfusion System Organ 
Transport System Inc, Frisco, TX, USA)
Porcine, non-DBD with 4 hours continuous 
perfusion followed by transplantation (29); 
Canine, DCD with 4 hours continuous 
perfusion followed by transplantation (30)
28 rejected or not offered donor hearts 
recovered using CSS, antegrade perfusion or 
retrograde perfusion for 12 hours followed by 
metabolic assessment (31)
HeartPort System (Modified Life Port System, 
Organ Recovery System, Itasca, IL, USA)
Porcine, non-DBD with 4 hours of 
continuous perfusion followed by 
Langendorff assessment for 60 minutes (32)
Paragonix Sherpa Perfusion™ Cardiac 
Transport System (Paragonix Technologies, 
Baintree, MA, USA)
Porcine, Non-DBD with 12 hours pulsatile 
perfusion followed by Langendorff 
assessment for 60 minutes (33)
HMP, hypothermic machine perfusion; DBD, donation after brain death; DCD, donation after circulatory death; CSS, cold static storage.
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hearts where adequate cardiac recovery is questionable. 
Regardless, the technology is here to stay not only for 
improved organ preservation and assessment, but also for 
extra corporeal therapy such as immune-modulation and 
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